Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI South Africa ETF (EZA) vs Cassava Sciences Inc (FLNA) Price & Performance

iShares MSCI South Africa ETFTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI South Africa ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI South Africa ETF trades at $68.5, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: iShares MSCI South Africa ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

EZAFLNA
Sector
Broad Market / FactorHealth
52-Week High
$81.60$4.64
52-Week Low
$56.57$0.87
Market Cap
$47.75M
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI South Africa ETF

EZA trades at $69.65, up 4.14% today, with a bullish technical signal from moving averages but overbought oscillators. The stock faces resistance near $68 and support at $66. Recent news highlights macroeconomic pressures on its South African-focused portfolio, including exposure to gold, banking, and platinum group metals amid rising interest rates and inflation.

The outlook is mixed, with technical strength offset by fundamental headwinds from global reflation. Investment opportunities hinge on commodity price stability, while risks include yield curve dynamics and cost of capital increases that may pressure constituent earnings.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About iShares MSCI South Africa ETF

EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.

Read more on EZA

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA